Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.16 | N/A | -90.55% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.16 | N/A | -90.55% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over the EPS results, indicating challenges in meeting expectations. They did not provide any forward guidance, leaving investors uncertain about future performance.
Management acknowledged the significant EPS miss compared to expectations.
No specific guidance was provided for future quarters.
The earnings report shows that Ligand Pharmaceuticals had a significant miss on EPS, which could raise concerns among investors about the company's financial health. Despite this, the stock reacted positively, increasing by 1.1%. This may indicate that investors are looking past the EPS miss, possibly due to other factors not disclosed in the earnings report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WESTERN DIGITAL CORP
Apr 29, 2019